444results about "Silicon compound active ingredients" patented technology

The invention discloses a general KRAS inhibitor, the structure of which is shown as a formula I. In the formula, the definition of each substituent group is shown in the description and claims. The general KRAS inhibitor has the advantages of easily available raw materials, simple synthesis, wide action range and strong effect, and can reduce or avoid the possibility of drug resistance generation. # imgabs0 #

The present invention relates to a nitrogen-containing tricyclic PRMT5 inhibitor, a method for producing the same, and a pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a structure represented by formula (I), a method for producing the same, a drug composition containing the same, and its use as a PRMT5 inhibitor and its use in the treatment and / or prevention of diseases mediated by PRMT5. Here, each substituent of formula (I) is the same as defined in the specification. 【Chemical 1】 TIFF2025516926000204.tif44144

The invention discloses a nitrogen-containing heterocyclic ring compound as well as a preparation method and application thereof, and particularly relates to a nitrogen-containing heterocyclic ring compound as shown in a general formula (I), or pharmaceutically acceptable salts thereof, or enantiomers, diastereoisomers, tautomers, torsion isomers, solvates, polymorphic substances or prodrugs thereof, and a preparation method and pharmaceutical application thereof. Wherein the definition of each group is described in the specification. # imgabs0 #

Disclosed herein are quaternary ammonium silane aqueous hydrogel formulations, including pharmaceutically acceptable aqueous hydrogel formulations, that provide high aqueous stability to an ammonium silane active moiety, as well as methods of use and manufacture.

The compound shown in formula I, its stereoisomers or pharmaceutically acceptable salts, or a pharmaceutical composition containing them, and their use in the manufacture of a therapeutic agent for treating related diseases as a PDE4B inhibitor, wherein each group shown in formula (I) is as defined in the specification. [Chemical formula 1] TIFF2025518257000169.tif37156

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4 / 6 (CDK4 / 6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.

The invention discloses magnesium-containing mesoporous active bioglass with drug sustained release, immunoregulation and bone metabolism regulation effects and application thereof. The drug-loaded MBGN is prepared by doping Mg ions and loading drugs, and the drug-loaded MBGN has good biocompatibility and can be decomposed in an acid environment to achieve controllable slow release of the drugs; on the other hand, released ions such as Si, Ca and Mg have a certain immunoregulation function, polarization of macrophages from M1 type to M2 type is promoted, inflammatory response is reduced, differentiation and maturation of osteoclasts are inhibited, and meanwhile, the released ions and drugs carried in mesopores play a synergistic effect, so that a good treatment effect is achieved. The drug-loaded MBGN provided by the invention has various biological properties, can overcome the defects of low drug loading rate, insufficient anti-inflammatory effect and the like when the existing mesoporous bioactive glass material is applied clinically, and has a good application prospect.

The present invention aims to provide a novel compound having SF-1 antagonist activity, a multifunctional molecule containing a moiety corresponding to the compound, particularly an SF-1 Degrader. The present invention relates to a 3-phenylpropylamine derivative compound represented by formula (1) etc., and a multifunctional molecule containing a moiety corresponding to the compound represented by formula (1) etc. JPEG0007688242000190.jpg40145

A method of selectively inhibiting pathogenic microbes includes: providing an antimicrobial compound that is functional having a structure of Formula 1, or derivative thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combination thereof; and contacting a microbe with the compound such that the microbe is selectively inhibited;

Provided herein are compounds and pharma- ceutically acceptable salts thereof useful as KRAS G12D and / or KRAS G12C inhibitors, methods of making and using them (alone or in combination with additional agents), and pharmaceutical compositions thereof. The KRAS protein, Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ("KRAS"), is a GTPase. KRAS gene mutations have been observed in several conditions, including, for example, pancreatic cancer, endometrial cancer, lung adenocarcinoma, colorectal cancer, rectal cancer, gallbladder cancer, thyroid cancer, cholangiocarcinoma, small cell lung cancer, and non-small cell lung cancer (NSCLC).

The invention relates to RIP1 inhibiting compounds and methods of making and using the same. In particular, disclosed herein are kinase inhibitory compounds, such as receptor interacting protein-1 (RIP1) kinase inhibitor compounds, and pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions and / or combinations may be used to treat or prevent kinase-related diseases or disorders, particularly RIP1-related diseases or disorders.

The present invention provides nitrogen-containing heterocyclic protein inhibitor compounds, their stereoisomers, tautomers or pharma- ceutically acceptable salts, and further provides the preparation of nitrogen-containing heterocyclic compounds and their uses, and medicaments prepared using such compounds have a wide range of uses in the treatment of diseases, including multiple types of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, lupus erythematosus, neurodermatitis, dermatitis, psoriasis, psoriatic arthritis, Crohn's disease, sicca syndrome and scleroderma.

The purpose of the present invention is to provide a novel compound having SF-1 antagonist activity, and a polyfunctional molecule comprising a moiety corresponding to this compound, particularly an SF-1 degrader. The present invention relates to a 3-phenylpropylamine derivative compound represented by formula (1), etc., and a polyfunctional molecule comprising a moiety corresponding to the compound represented by formula (1), etc.

The present invention relates to heterocyclic compounds, pharmaceutical compositions thereof, and methods which may be useful as inhibitors of IGF-1R for the treatment or prevention of thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy (TAO), or Graves' ophthalmopathy or orbitopathy (GO).

The present disclosure provides nitrogen-containing silicon ether ionizable lipid compounds and lipid nanoparticles including the ionizable lipid. The disclosure further relates to lipid nanoparticles including a provided ionizable lipid compound together with a phospholipid, e.g., a phospholipid that includes at least one unsaturated tail and a head group having a positively charged nitrogen. The provided materials are particularly beneficial in applications involving delivery of a nucleic acid. The disclosure also provides pharmaceutical compositions and methods including the provided ionizable lipids and / or lipid nanoparticles.

Compounds and compositions capable of modulating immune responses in patients, as well as implantable elements containing them, are provided. [Solution] For example, 4-((1-(2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)thiomorpholine 1,1-dioxide, as well as pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives and compositions thereof, and implantable elements (e.g., devices and materials) containing these are provided.

The present invention relates to a stable silicic acid solution having a silicon content of 0.01-1.00% w / w. Silicic acid is stabilized by the combination of amino acid bisulfate 1AA, 1b, 1c, amino acid sodium and / or potassium 2aAA, 2bAA, 2c, 2d, 2e, 2f and sodium and / or potassium bisulfate (NaHSO4 and / or KHSO4) in a mixture of diol, 1, 2-propylene glycol (3) and / or polyethylene glycol (4) and purified water. The present invention discloses a method for preparing such a formulation. The composition is used as a food supplement, a functional food ingredient, a feed additive, a functional feed additive, a biostimulant for aquaculture, an active cosmetic ingredient, an active pharmaceutical ingredient, an agrochemical product and the like, and provides high bioavailability silicon (Si).

The present application provides a compound of formula (I) or a pharmaceutically acceptable salt thereof. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof is provided. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a CYP1A1 inhibitor is provided. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing tumors, bacterial infections, sepsis, inflammation, or organ damage is provided.

The present disclosure relates to tricyclic tetrahydroisoquinoline derivatives, their preparation methods, and their pharmaceutical applications. In particular, the present disclosure relates to tricyclic tetrahydroisoquinoline derivatives represented by general formula (I), their preparation methods, pharmaceutical compositions containing the derivatives, and their use as estrogen receptor modulators and in the preparation of drugs for treating estrogen receptor-mediated or dependent diseases or disorders. wherein, each substituent in general formula (I) is as defined in the specification. TIFF2023509944000122.tif5353

The invention relates to the technical field of medical dressings, and discloses a scar repair gel containing recombinant mussel mucin and a preparation method thereof. The scar repair gel is prepared from the following components in percentage by mass: 0.01 to 0.2 percent of recombinant mussel mucin, 0.4 to 0.8 percent of a thickening agent, 6 to 15 percent of a compound emulsifier, 1 to 2 percent of a pH regulator, 20 to 40 percent of silicone, 0.1 to 0.3 percent of a preservative and the balance of water, wherein the silicone comprises polydimethylsiloxane, a polydimethylsiloxane cross-linking agent and decamethylcyclopentasiloxane. The scar repair gel containing the recombinant mussel mucin has good film-forming property, forms a moisturizing barrier on the surface of a wound, can inhibit formation of hyperplasia scars, reduces pruritus in the wound healing process, reduces generation and deposition of melanin, and has the effects of repairing scars and repairing scars. The comfort of a patient in the use process and the compounding stability of the mussel mucin and silicone gel system are effectively improved.

The present disclosure provides compounds, compositions, and methods for treating or preventing neurological disorders in a patient. The disclosed methods include administration to a subject suffering from a neurological disorder of a compound disclosed herein.

To provide a novel organosilicon quaternary ammonium compound that is effective in infectious disease.SOLUTION: A quaternary ammonium compound of the following formula is provided. In the formula, R2,R3, R4, R22, R23, and R24 are individually independent and selected from the group consisting of the following.SELECTED DRAWING: None

The present disclosure provides compounds of Formula I: (I), or an N- oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

[Problem] To provide a medicine capable of preventing or treating non-alcoholic fatty liver disease, pain associated with inactivity or acute pancreatitis, etc. [Solution] Non-alcoholic fatty liver disease, pain associated with inactivity and acute pancreatitis can be prevented or treated by orally administering fine silicon particles or placing the same on the skin or a mucosa. The fine silicon particles are particles that generate hydrogen when coming into contact with an aqueous solution of pH 7 or higher. Provided are a preventive or therapeutic agent for non-alcoholic fatty liver disease, pain associated with inactivity or acute pancreatitis, a medicinal composition, a medical instrument, a food or a beverage, each containing the fine silicon particles. Preferably, the fine silicon particles are ultrafine silicon particles and / or an aggregate of the ultrafine silicon particles.

The present invention relates to a composition comprising:-an organosilicon compound of formula (I) RxSi (OH) 4-x, in which each R is independently a group containing from 1 to 20 carbon atoms, x = 1 to 3, or a salt thereof; and-a cross-linked glycosaminoglycan or a salt thereof.

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B. The compounds can be used alone or in combination with other drugs. TIFF2023509881001359.tif33128

The monoclonal antibody specifically binds to CD25, and the conjugate of anti-CD25 antibody are described.The CD25-specific monoclonal antibody and its conjugate do not block the binding of IL-2 to CD25, and induce little or no antibody-dependent cell-mediated cytotoxicity (ADCC).The anti-CD25 antibody and conjugate can be used, for example, to target photoimmunotherapy to T regulatory (Treg) cells in tumor beds to enhance local host immune response against tumors.

The present disclosure provides a compound of formula I:(1), or an N-oxide thereof, or a pharmaceutically acceptable salt of said compound or N-oxide, wherein A, Y, m, n, p, R 1 , R 2 , R 3 , R 3a , R 4 , R 5 , R 6 , R 7 and Z are as described herein; processes for their preparation; intermediates used in their preparation; and compositions containing such compounds, N-oxides or salts, and their uses for treating M4-mediated (or M4-associated) disorders, including, for example, Alzheimer's disease, Parkinson's disease, schizophrenia (e.g., the cognitive and negative symptoms thereof), pain, addiction, and sleep disorders.